Company Filing History:
Years Active: 2005
Title: The Innovative Contributions of Brain A. Zabel
Introduction
Brain A. Zabel, based in Stanford, California, is a noteworthy inventor who has made significant strides in the field of biotechnology. With a keen focus on the modulation of immune responses, Zabel has developed innovative methods that have the potential to enhance therapeutic strategies related to immune system functions.
Latest Patents
Zabel holds a patent titled "Methods of inhibiting GPR-9-6 function." This invention pertains to an antibody or an antigen-binding fragment that specifically binds to the CC chemokine receptor GPR-9-6. Notably, the invention effectively blocks the binding of ligands, such as TECK, to this receptor. Zabel's patent also outlines methods for identifying agents—ranging from molecules to compounds—that can inhibit ligand binding, as well as methods to modulate the function of GPR-9-6. The applicability of this invention spans research, therapeutic, prophylactic, and diagnostic methods, making it a versatile tool in the field.
Career Highlights
Currently, Brain A. Zabel is affiliated with Millennium Pharmaceuticals Limited, a leader in biopharmaceutical innovation. Throughout his career, Zabel has focused on advancing scientific knowledge and developing solutions to complex medical challenges.
Collaborations
Zabel's work has been complemented by his collaborations with esteemed colleagues, including David P. Andrew and Paul D. Ponath. These partnerships underscore Zabel's commitment to teamwork and knowledge-sharing in the pursuit of scientific advancements.
Conclusion
Through his innovative patent and collaborative spirit, Brain A. Zabel exemplifies the role of inventors in revolutionizing biotechnology. His focus on GPR-9-6 illustrates the potential for targeted therapies that enhance our understanding and treatment of immune-related conditions. Zabel's contributions not only reflect his dedication as an inventor but also pave the way for future discoveries in the field.